In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WerfenLife Group SA

www.werfenlife.com

Latest From WerfenLife Group SA

German Industry Says MDR Implementation 'Too Slow' But Negative Economic Effects Still Largely Unreported

The European Commission needs to be faster and more efficient in its implementation of the new EU Medical Device Regulation (MDR), say German manufacturers, watching the remaining months of transition time slip into single figures. A few economic operators have come clean about the pressure the MDR has brought to bear, but the suspicion is that many are choosing to keep quiet.   

EU Germany

Device/Diagnostics Quarterly Deal-Making Statistics, Q1 2017

Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings – totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) – showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.

Medical Device In Vitro Diagnostics

TEVAR 2016: Companies Push New Frontiers In Thoracic Aortic Interventions

Although thoracic endovascular aortic repair (TEVAR) is now routine for lesions like dissection of the descending aorta, the Big Three aortic endovascular companies are developing devices for the more technically challenging proximal and distal portions of the thoracic aorta while physicians refine TEVAR in the descending aorta. Insiders say endovascular techniques are overcoming limitations and physicians will soon be able to treat the entire aorta, from the aortic valve to the bifurcation.

Innovation Commercial

EVAR Update: Competitors Stake Their Ground In A High-Growth Space

The endovascular abdominal aortic aneurysm repair (EVAR) market is one of the brightest growth opportunities in the medical device arena today. As a result, the competitive landscape is heating up as several new entrants stake their claim for a share of this $1+ billion opportunity.

Medical Device
See All

Company Information

  • Industry
  • Distributors
  • In Vitro Diagnostics
  • Medical Devices
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Immune Disorders
  • Alias(es)
  • Werfen Life Group SA
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Spain
  • Parent & Subsidiaries
  • WerfenLife Group SA
  • Senior Management
  • Jordi Rubiralta, Pres.
  • Contact Info
  • WerfenLife Group SA
    Phone: (34) 93 4010101
    Plaza de Europa nº 21-23
    Barcelona, 08908
    Spain
UsernamePublicRestriction

Register